Business Description
Tevogen Bio Holdings Inc
NAICS : 541714
SIC : 8731
Description
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.56 | |||||
| Equity-to-Asset | -2.31 | |||||
| Debt-to-Equity | -0.26 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.39 | |||||
| 9-Day RSI | 27.67 | |||||
| 14-Day RSI | 30.63 | |||||
| 6-1 Month Momentum % | -91.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.23 | |||||
| Quick Ratio | 0.23 | |||||
| Cash Ratio | 0.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 84.91 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -0.04 | |||||
| ROA % | -111.56 | |||||
| ROIC % | -29.68 | |||||
| ROC (Joel Greenblatt) % | -928.12 | |||||
| ROCE % | 0.1 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.98 | |||||
| PE Ratio without NRI | 6.18 | |||||
| EV-to-EBIT | -10.26 | |||||
| EV-to-EBITDA | -10.26 | |||||
| EV-to-FCF | -26.34 | |||||
| Earnings Yield (Greenblatt) % | -9.74 | |||||
| FCF Yield % | -3.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tevogen Bio Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.276 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 30.63 | ||
| 14-Day ATR (€) | 0.032001 | ||
| 20-Day SMA (€) | 0.46715 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.352 - 8.418 | ||
| Shares Outstanding (Mil) | 170.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tevogen Bio Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tevogen Bio Holdings Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tevogen Bio Holdings Inc Frequently Asked Questions
What is Tevogen Bio Holdings Inc(FRA:G28)'s stock price today?
The current price of FRA:G28 is €0.37. The 52 week high of FRA:G28 is €8.42 and 52 week low is €0.35.
When is next earnings date of Tevogen Bio Holdings Inc(FRA:G28)?
The next earnings date of Tevogen Bio Holdings Inc(FRA:G28) is 2024-11-29 Est..
Does Tevogen Bio Holdings Inc(FRA:G28) pay dividends? If so, how much?
Tevogen Bio Holdings Inc(FRA:G28) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers